BioPharma Credit PLC Dividend Declaration (2593R)
November 04 2021 - 3:00AM
UK Regulatory
TIDMBPCR
RNS Number : 2593R
BioPharma Credit PLC
04 November 2021
BIOPHARMA CREDIT PLC
("BIOPHARMA CREDIT" OR THE "COMPANY")
DIVIDEND DECLARATION
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences
debt investor, is pleased to declare an interim dividend in respect
of the financial period ending 30 September 2021 of $0.01750000 per
ordinary share, payable on 17 December 2021 to ordinary
shareholders on the register as at 19 November 2021. The Company
has chosen to designate part of this interim dividend as an
interest distribution. The dividend will be paid as 0.01605138
cents per share as an interest payment and 0.00144862 cents per
share as an ordinary dividend. Shareholders in receipt of such a
dividend will be treated for UK tax purposes as though they have
received a payment of interest in respect of the interest
distribution element of this dividend. This will result in a
reduction in the corporation tax payable by the Company.
The Company is currently paying and continues to target a 7 cent
annual dividend per ordinary share.
The default payment for dividends is in US dollars. However,
shareholders can elect to have dividends paid in sterling (GBP) and
the option to elect a sterling dividend payment for this dividend
will be available to shareholders until 19 November 2021 (the
"Election Date").
Further details together with a copy of the Dividend Currency
Election Form, which should be sent to Link Group, 10th Floor,
Central Square, 29 Wellington Street, Leeds LS1 4DL when completed,
will be available on the Group's website shortly at
www.bpcruk.com/investor-materials . CREST shareholders must elect
via CREST.
LEI: 213800AV55PYXAS7SY24
-Ends-
Link Company Matters Limited
Company Secretary
4 November 2021
Enquiries:
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
Biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor
in debt from the life sciences industry and joined the LSE on 27
March 2017. The Company seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry. The
Company seeks to achieve this objective primarily through
investments in debt assets secured by royalties or other cash flows
derived from the sales of approved life sciences products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DIVBJBATMTAMBJB
(END) Dow Jones Newswires
November 04, 2021 03:00 ET (07:00 GMT)
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From Apr 2024 to May 2024
Biopharma Credit (LSE:BPCR)
Historical Stock Chart
From May 2023 to May 2024